Search: id:"swepub:oai:lup.lub.lu.se:6b23654c-9ccf-4cfb-b503-355c45c5115b" >
Gene expression pro...
-
Theilgaard-Moench, KimLund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine
(author)
Gene expression profiling in MDS and AML: potential and future avenues.
- Article/chapterEnglish2011
Publisher, publication year, extent ...
-
2011-03-29
-
Springer Science and Business Media LLC,2011
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:6b23654c-9ccf-4cfb-b503-355c45c5115b
-
https://lup.lub.lu.se/record/1883358URI
-
https://doi.org/10.1038/leu.2011.48DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.Leukemia advance online publication, 29 March 2011; doi:10.1038/leu.2011.48.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Boultwood, J
(author)
-
Ferrari, S
(author)
-
Giannopoulos, K
(author)
-
Hernandez-Rivas, J M
(author)
-
Kohlmann, A
(author)
-
Morgan, M
(author)
-
Porse, B
(author)
-
Tagliafico, E
(author)
-
Zwaan, C M
(author)
-
Wainscoat, J
(author)
-
Van den Heuvel-Eibrink, M M
(author)
-
Mills, K
(author)
-
Bullinger, L
(author)
-
Stamcellscentrum (SCC)Avdelningen för stamcellsforskning
(creator_code:org_t)
Related titles
-
In:Leukemia: Springer Science and Business Media LLC25:6, s. 909-9201476-55510887-6924
Internet link
Find in a library
-
Leukemia
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Theilgaard-Moenc ...
-
Boultwood, J
-
Ferrari, S
-
Giannopoulos, K
-
Hernandez-Rivas, ...
-
Kohlmann, A
-
show more...
-
Morgan, M
-
Porse, B
-
Tagliafico, E
-
Zwaan, C M
-
Wainscoat, J
-
Van den Heuvel-E ...
-
Mills, K
-
Bullinger, L
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Leukemia
- By the university
-
Lund University